A Randomized Trial of the Combination of Ridaforolimus and Exemestane, compared to Ridaforolimus, Dalotuzumab and Exemestane in High proliferation, Estrogen recpptor positive Breast Cancer Patients
|Effective start/end date||4/23/12 → 4/30/17|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.